Fox Chase study ties protein to cancer drug resistance in mice
- Posted: December 10, 2012
Blocking a specific protein renders tumors more vulnerable to treatment in mice, suggesting new therapies could eventually achieve the same in humans, according to new research from Fox Chase Cancer Center presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium. The protein in question is a type of ATP-binding cassette drug efflux pumps, known more simply as ABC proteins. These proteins sit on the membranes of cells, where they act just like pumps—removing cancer drugs from the cell, thereby making them less effective.
Among the research institutions NCI funds across the United States, it currently designates 67 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.